Printer Friendly
The Free Library
19,595,263 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Applied Biosystems Announces Launch of Micro Fluidic Card for Parallel, High Throughput Gene Expression Analysis.


Business Editors/Health/Medical Writers

BIOWIRE2K

FOSTER CITY, Calif.--(BUSINESS WIRE)--May 13, 2003

Applied Biosystems Applied Biosystems, Inc. (formerly NASDAQ: ABIO) is the original name of a pioneer biotechnology company founded in 1981 in Foster City, California, among the Silicon Valley cities of the southern San Francisco Bay Area.  Group (NYSE NYSE

See: New York Stock Exchange
:ABI Abi (ā`bī) [short for Abijah], in the Bible, King Hezekiah's mother.


(Application Binary Interface) A specification for a specific hardware platform combined with the operating system.
), an Applera Corporation business, today introduced the Applied Biosystems 7900HT Micro Fluidic flu·id·ic  
adj.
1. Of, relating to, or characteristic of a fluid.

2. Relating to or controlled by fluidics.
 Card, an assay system designed for customization with the Applied Biosystems Assays-on-Demand(TM) Gene Expression Products for use on the ABI PRISM (R)7900HT Sequence Detection System.

The Applied Biosystems 7900HT Micro Fluidic Card allows high throughput, parallel analysis of gene expression patterns, and is expected to expedite customers' target discovery programs by allowing researchers to investigate complex biological pathways more quickly and cost-effectively. The 7900HT Micro Fluidic Card is designed for custom configuration using the Applied Biosystems Assays-on-Demand(TM) Gene Expression Products for both human and mouse genes. Customers can create their own micro card configuration online by selecting from over 26,000 Applied Biosystems Assays-on-Demand(TM) Gene Expression Products, which include more than 18,000 gene-specific assays for human genes and over 8,000 gene-specific assays for mouse genes.

"Real-Time PCR PCR polymerase chain reaction.

PCR
abbr.
polymerase chain reaction


Polymerase chain reaction (PCR) 
 using TaqMan(R) probes is a very precise analytical method for the analysis of gene expression. The 7900HT Micro Fluidic Card represents another advance in gene expression technologies from Applied Biosystems that should allow customers to take advantage of this gold standard technology, not only for examining one or a few genes but even tens to hundreds of genes at a time," said Michael W. Hunkapiller, Ph.D., President of Applied Biosystems. "As a result, scientists can look at larger collections of genes to ultimately better understand the pathways and networks involved in complex biological systems."

Online Ordering

The Applied Biosystems 7900HT Micro Fluidic Card can be ordered through the recently enhanced Applied Biosystems e-commerce site at http://store.appliedbiosystems.com/. The 7900HT Micro Fluidic Card is a micro reaction vessel system that supports up to 10 different configuration options with 12-384 assays per card. Interested parties may browse the online catalog Similar to an online library or databases in the information storage respect, ‘’’online catalogs’’’ allow potential customers to browse a company’s items for sale from a different location using the internet.  of assays free of charge. The 7900HT Micro Fluidic Card was developed in partnership with 3M of St. Paul, Minnesota through a collaboration formed in 1999. The collaboration combines 3M's strengths in material science and manufacturing with Applied Biosystems' strengths in genetic analysis science and technology.

About Applera Corporation and Applied Biosystems

Applera Corporation comprises two operating groups. The Applied Biosystems Group develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids Nucleic acids
The cellular molecules DNA and RNA that act as coded instructions for the production of proteins and are copied for transmission of inherited traits.
 (DNA DNA: see nucleic acid.
DNA
 or deoxyribonucleic acid

One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes.
 and RNA RNA: see nucleic acid.
RNA
 in full ribonucleic acid

One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic
), small molecules, and proteins to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2002. The Celera Genomics Group (NYSE:CRA See Community Reinvestment Act. ), located in Rockville, MD, and South San Francisco South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , CA, is engaged principally in integrating advanced technologies to discover and develop new therapeutics. Celera intends to leverage its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop new therapeutics. Its Celera Discovery System(TM) online platform, marketed exclusively through the Applied Biosystems Knowledge Business, is an integrated source of information based on the human genome and other biological and medical sources. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of novel diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com.

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "should" and "expect," among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995 provides a "safe harbor Safe Harbor

1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated.

2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive.
" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to (1) sales dependent on customers' capital spending capital spending

Spending for long-term assets such as factories, equipment, machinery, and buildings that permits the production of more goods and services in future years.
 policies and government-sponsored research; (2) Applied Biosystems' dependence on the operation of computer hardware, software, and Internet applications and related technology; (3) unproven use of genomics information to develop or commercialize products; (4) rapidly changing technology and dependence on development of new products and; (5) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

For Research Use Only. Not for use in diagnostic procedures.

ABI PRISM and Applied Biosystems are a registered trademarks and AB (Design), Applera, Assays-on-Demand, Celera, Celera Discovery System, and Celera Genomics are trademarks of Applera Corporation and/or its subsidiaries in the U.S. and certain other countries.

TaqMan is a registered trademark of Roche Molecular Systems, Inc.

The PCR process and 5' nuclease nuclease /nu·cle·ase/ (noo´kle-as) any of a group of enzymes that split nucleic acids into nucleotides and other products.

nu·cle·ase
n.
 process are covered by patents owned by Roche Molecular Systems, Inc. and F. Hoffmann-La Roche Ltd.

The Micro Fluidic Card was developed in collaboration with 3M Corp.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:May 13, 2003
Words:887
Previous Article:Colorado MEDtech, Inc. Announces Third-Quarter Results.
Next Article:Applied Biosystems Announces Availability of Mouse Genomic Assays for Real-Time Gene Expression Analysis.
Topics:



Related Articles
Phase-1 Molecular Toxicology and PE Biosystems Sign Agreement for Development of Gene Expression Assays.
PE Biosystems Announces Launch Of ABI PRISM 7900HT Sequence Detection System.
Applied Biosystems Announces Availability of Mouse Genomic Assays for Real-Time Gene Expression Analysis.
Applied Biosystems Announces Availability of Rat Genomic Assays for Real-Time Gene Expression Analysis.
Applied Biosystems Announces First System for Whole Human Genome Analysis Using a Single Microarray.
Applied Biosystems Announces Availability of Two New Real-Time PCR Systems.
Quantitative PCR deconstruction of discrepancies between results reported by different hybridization platforms.
Applied Biosystems Annnounces Major Expansion of Its TaqMan Gene Expression Assays Product Line for Real-Time PCR.
Applied Biosystems Introduces New TaqMan(R) Low Density Array Gene Signature Panels for Common Drug Targets; Expansion of TaqMan Low Density Array...
Applied Biosystems Advanced Gene Expression Service Provider Program Expands Globally; Researchers in North America, Europe, and Asia Outsource...

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles